Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging

Eur Urol Focus. 2021 May;7(3):503-505. doi: 10.1016/j.euf.2021.03.027. Epub 2021 Apr 23.


ReIMAGINE Screening is a single-centre study assessing the feasibility of biparametric magnetic resonance imaging as a screening tool for prostate cancer. The study outcomes will take us a step towards more accurate and less harmful prostate cancer screening.

Trial registration: ClinicalTrials.gov NCT04063566.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Early Detection of Cancer*
  • Humans
  • Magnetic Resonance Imaging / methods
  • Male
  • Prostate-Specific Antigen
  • Prostatic Neoplasms* / pathology


  • Prostate-Specific Antigen

Associated data

  • ClinicalTrials.gov/NCT04063566